Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

70.93EUR
17 Nov 2017
Change (% chg)

€1.10 (+1.57%)
Prev Close
€69.84
Open
€70.29
Day's High
€70.93
Day's Low
€70.29
Volume
109
Avg. Vol
1,046
52-wk High
€81.75
52-wk Low
€59.00

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.18 15.80
EPS (TTM): -- -- --
ROI: -- 15.02 12.07
ROE: -- 16.37 16.02

Lilly mulls sale, other options for animal health business

Eli Lilly and Co said on Tuesday it is considering the sale of its Elanco animal health business and expressed optimism that its rejected rheumatoid arthritis drug would pass muster with U.S. regulators when it resubmits its application.

Oct 24 2017

BRIEF-Lilly "very optimistic" on U.S. prospect for arthritis drug

* Eli Lilly says "very optimistic" on U.S. prospect for arthritis drug baricitinib; still sees resubmission to FDA by January Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

Oct 24 2017

Eli Lilly says profit falls, to mull sale of animal health business

Oct 24 Eli Lilly and Co, one of the world's top insulin makers, on Tuesday reported a 28.5 percent drop in quarterly profit and said it was reviewing options, including a sale or an IPO, for its Elanco Animal Health business.

Oct 24 2017

BRIEF-Novo Nordisk VP says seeks market share from Eli Lilly with semaglutide

Oct 19 NOVO NORDISK CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN SAYS IN INTERVIEW:

Oct 19 2017

BRIEF-Eli Lilly ‍declares Q4 dividend of $0.52/share

* Declared a dividend for Q4 of 2017 of $0.52 per share on outstanding common stock​ Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-Eli Lilly sets quarterly dividend of $0.52 per share

* Sets quarterly dividend of $0.52 per share Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-‍BIOLOGICS SAYS SELECTED BY ELI LILLY TO BE IN LIMITED DISTRIBUTION NETWORK FOR VERZENIO​

* ‍BIOLOGICS INC SAYS HAS BEEN SELECTED BY ELI LILLY AND COMPANY TO BE IN LIMITED DISTRIBUTION NETWORK FOR VERZENIO​ Source text for Eikon: Further company coverage:

Oct 11 2017

BRIEF-U.S. PTO rules in Eli Lilly's favor on Alimta

* Patent trial and appeal board of U.S. PTO ruled in company's favor regarding patentability of vitamin regimen for Alimta

Oct 05 2017

BRIEF-Eli lilly says Lilly Endowment Inc reports open market sale of 205,000 shares of co's common stock on Oct. 4

* Eli lilly and co says Lilly Endowment Inc reports open market sale of 205,000 shares of co's common stock on OCT. 4 at average price of $86.805 per share - SEC filing Source text for Eikon: Further company coverage:

Oct 05 2017

BRIEF-Eli Lilly's ‍Humalog Junior Kwikpen now available by prescription in U.S.​

* Eli Lilly and Co - ‍Humalog Junior Kwikpen now available by prescription for treatment of diabetes in U.S.​ Source text for Eikon: Further company coverage:

Oct 04 2017

Earnings vs. Estimates